First-line treatment with nivolumab plus ipilimumab (NIVO+IPI) results in better survival and response benefits in patients with advanced renal cell carcinoma (aRCC) when compared with sunitinib (SUN), as shown by long-term follow-up data from the CheckMate 214 trial.
Pembrolizumab (pembro) plus lenvatinib (lenva) provides durable antitumour activity in patients with advanced nonclear cell renal cell carcinoma (nccRCC) and has a manageable safety profile, according to the results of the phase II KEYNOTE-B61 study.
First-line pembrolizumab (pembro) plus chemotherapy (chemo) in patients with untreated advanced esophageal cancer demonstrates robust efficacy after 5 years, with no new safety concerns, when compared with placebo plus chemo, according to a study presented at ASCO GI 2024.
Hand grip may be associated with clinical disease activity in patients with Crohn’s disease (CD), but hand grip measurements alone may not be the best predictor of disease activity or related disability, suggests a study presented at Crohn’s and Colitis Congress 2024.
In a study presented at Crohn’s and Colitis Congress 2024, infliximab and vedolizumab were found to have similar effectiveness in achieving steroid-free clinical remission (SFCR) and biochemical remission (BR) at 12 months when used as first-line treatment for biologic-naïve paediatric patients with uncomplicated mild-to-moderately active inflammatory bowel disease (IBD).
The risk of developing serious infections is much lower among patients with Crohn’s disease (CD) who showed response to adalimumab therapy than nonresponders, after accounting for disease severity, according to the results of a study presented at CCC 2024.
Multiple biosimilar infliximab (IFX) switching among patients with inflammatory bowel disease (IBD) does not seem to give rise to disease flares at 12 months compared to those who continued using IFX originator or those on single IFX biosimilar switch, a study has shown.
In Asian patients with esophageal squamous cell carcinoma (ESCC), adding the TIGIT inhibitor tiragolumab and PD-L1 inhibitor atezolizumab to chemotherapy improved all outcomes in the phase III SKYSCRAPER-08 trial.